BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial

BACKGROUND AND AIMS: Hepatic fibrosis secondary to HCV infection can lead to cirrhosis and hepatic decompensation. Sustained virologic response (SVR) is possible with direct‐acting antiviral drug regimens; however, patients with advanced fibrosis have an increased risk for HCC. Heat shock protein 47...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawitz, Eric J., Shevell, Diane E., Tirucherai, Giridhar S., Du, Shuyan, Chen, Warner, Kavita, Uma, Coste, Angie, Poordad, Fred, Karsdal, Morten, Nielsen, Mette, Goodman, Zachary, Charles, Edgar D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299674/
https://www.ncbi.nlm.nih.gov/pubmed/34605045
http://dx.doi.org/10.1002/hep.32181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299674/
https://www.ncbi.nlm.nih.gov/pubmed/34605045
http://dx.doi.org/10.1002/hep.32181

Ejemplares similares